Recent advances in neurobiology and PET have helped redefine Alzheimer's disease (AD) as a dynamic pathophysiological process, clinically characterized by preclinical, mild cognitive impairment ...
Galantamine provides the clinician with another choice of an AChE inhibitor for use in treating AD. Since galantamine has a dual mechanism of action -- both inhibiting AChE and modulating ...